China CDC

China CDC
No new digest content identified.


National Health Commission of the People’s Republic of China
Aug 29: Daily briefing on novel coronavirus cases in China
On Aug 28, 31 provincial-level regions and the Xinjiang Production and Construction Corps on the Chinese mainland reported 9 new cases of confirmed infections.

COVID-19 vaccine candidate produced from insect cells to enter human trials
Updated: 2020-08-26
CHENGDU — China has approved human trials for a new COVID-19 vaccine candidate, which was produced by the use of insect cells.
The recombinant protein vaccine was issued with a clinical research permit from the National Medical Products Administration, said the vaccine developer the West China Hospital of Sichuan University on Aug 24.
According to hospital researchers, it will be China’s first COVID-19 vaccine candidate grown in insect cells on humans. The vaccine is designed to trigger antibodies against specific areas on the spike protein of SARS-CoV-2, the virus that causes COVID-19.
Results of animal tests were published in the journal Nature on July 29, which showed that the vaccine could induce immune responses against SARS-CoV-2 infection in mice, rabbits and non-human primates as early as seven or 14 days after a single dose injection, with no obvious side effects.
Co-author Wei Yuquan, a senior researcher of the hospital’s state key laboratory of biotherapy, said the vaccine was produced by inserting genes of the SARS-CoV-2 virus into insect cell cultures, which can grow viral proteins. Such an approach is suitable for large-scale manufacturing of vaccines…